| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $20,195,184 ) (Continued on the next page) |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R03DE036072 | Impact of Reduced-Exposure Nicotine Product Use on Oral Health Conditions among the High-Risk Population | 000 | 1 | NIH | 7/10/2026 | $347,000 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01MH126282 | Investigating how stress induced changes in maternal serotonin affect offspring development and stress resilience | 000 | 6 | NIH | 3/5/2026 | $429,250 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA267647 | Delineating the dystopian nature of the cell cycle in cancer | 000 | 5 | NIH | 5/13/2026 | $534,959 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R50CA211108 | Associate-Director Flow and Image Cytometry Roswell Park ComprehensiveCancer Center | 000 | 10 | NIH | 7/10/2026 | $342,107 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA305978 | Elucidating mechanisms underlying lung cancer lineage plasticity thatfacilitate adaptation and resistance to targeted therapy | 000 | 1 | NIH | 6/5/2026 | $719,951 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA312294 | Elucidating the impacts of body composition and physical activity on anti-tumor immunity and cancer control in advanced stage high-grade serous carcinoma | 000 | 1 | NIH | 5/22/2026 | $713,312 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA272771 | The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer | 000 | 4 | NIH | 2/27/2026 | $468,436 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA279440 | The Immunomodulatory Function of Cyclin E1 in Ovarian Cancer and Therapeutic Targeting | 000 | 3 | NIH | 3/19/2026 | $505,851 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA292730 | Decipher the Molecular Mechanisms of Breast Cancer Bone Metastasis | 000 | 2 | NIH | 3/3/2026 | $689,007 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA283547 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction | 000 | 3 | NIH | 2/27/2026 | $670,321 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | P30CA016056 | Roswell Park Cancer Center Support Grant | 000 | 49 | NIH | 7/7/2026 | $4,468,904 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01ES034250 | STAG2 modulates environmental toxicant exposures and epigenomic heterogeneity | 000 | 5 | NIH | 1/1/2026 | $597,213 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA283501 | MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication | 001 | 3 | NIH | 4/17/2026 | $31,622 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA283501 | MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication | 000 | 3 | NIH | 4/1/2026 | $640,437 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | K08CA286765 | Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL | 000 | 4 | NIH | 6/23/2026 | $196,110 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA248018 | Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies | 003 | 6 | NIH | 4/28/2026 | $396,881 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA292639 | Targeting retrotransposons for improved treatment of refractory childhood cancer | 001 | 3 | NIH | 7/16/2026 | $224,100 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA292639 | Targeting retrotransposons for improved treatment of refractory childhood cancer | 000 | 3 | NIH | 7/7/2026 | $360,011 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R35GM148071 | The Genetic Basis of Human DNA Replication Timing | 000 | 4 | NIH | 3/26/2026 | $458,040 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01DA057228 | Assessing pharmacokinetic and pharmacodynamic variability of Δ9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotine | 000 | 5 | NIH | 7/1/2026 | $635,648 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01MD016850 | Implementation of evidence-based strategies to optimize HPV vaccination in rural primary care settings | 000 | 5 | NIH | 6/9/2026 | $527,764 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA278802 | TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors | 000 | 4 | NIH | 6/18/2026 | $698,501 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA275961 | Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma | 001 | 4 | NIH | 4/16/2026 | $52,319 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA275961 | Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma | 000 | 4 | NIH | 12/17/2025 | $470,879 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA273231 | Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression | 000 | 5 | NIH | 7/21/2026 | $402,190 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA296175 | A scalable cruciferous vegetable intervention to reduce bladder cancer recurrence and progression | 001 | 2 | NIH | 4/15/2026 | $66,423 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA296175 | A scalable cruciferous vegetable intervention to reduce bladder cancer recurrence and progression | 000 | 2 | NIH | 12/23/2025 | $597,807 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA258337 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | 001 | 5 | NIH | 4/17/2026 | $63,219 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA258337 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | 000 | 5 | NIH | 12/12/2025 | $568,979 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA285707 | Determining the Impact of Metabolic Adaptations on the Immune-Tumor Microenvironment in Metastatic Breast Cancer | 001 | 2 | NIH | 4/16/2026 | $71,908 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA285707 | Determining the Impact of Metabolic Adaptations on the Immune-Tumor Microenvironment in Metastatic Breast Cancer | 000 | 2 | NIH | 12/19/2025 | $647,178 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA266216 | Induction of interferon response by chromatin damaging anti-cancer therapy | 001 | 3 | NIH | 4/16/2026 | $39,688 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA266216 | Induction of interferon response by chromatin damaging anti-cancer therapy | 000 | 3 | NIH | 12/18/2025 | $357,193 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA275081 | Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment | 000 | 4 | NIH | 7/3/2026 | $505,216 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA308972 | Modeling neuroendocrine bladder cancer for studying the pathogenesis and improving chemotherapy responses | 000 | 1 | NIH | 4/8/2026 | $639,379 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R21CA313682 | Enhanced targeted therapy for colorectal cancer | 000 | 1 | NIH | 7/3/2026 | $446,112 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R21CA308180 | Identification of age-regulating breast cancer dormancy genes using C. elegans dauers | 000 | 1 | NIH | 7/6/2026 | $446,112 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA304753 | Innate lymphoid Cells Drive Young Onset Lung Cancer Incidences in Females | 000 | 1 | NIH | 7/10/2026 | $706,579 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01HL167232 | Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation | 000 | 4 | NIH | 3/26/2026 | $675,727 |
| | 2026 | 2026 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA240290 | Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells | 000 | 7 | NIH | 4/21/2026 | $473,358 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA255515 | Metformin for chemoprevention of lung cancer in obese subjects at high risk | 000 | 5 | NIH | 5/5/2026 | $0 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA246437 | Hsp60 Regulation of Prostate Cancer Progression | 000 | 5 | NIH | 6/2/2026 | $0 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U01CA256801 | Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer | 000 | 5 | NIH | 2/5/2026 | $0 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA305623 | Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center | 000 | 1 | NIH | 1/15/2026 | $0 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01AI155499 | Understanding mechanisms and consequences of T cell co-receptor regulated RNA maturation | 000 | 5 | NIH | 7/22/2026 | $0 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA255242 | Advancing skin cancer prevention by tackling UV-induced clonogenic mutations | 000 | 5 | NIH | 2/12/2026 | $0 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R21CA288931 | Combined inhibition of ATR and p110β as Therapy in PTEN-deficient Prostate Cancer | 000 | 2 | NIH | 2/2/2026 | $0 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | UH3CA260602 | Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting | 000 | 5 | NIH | 4/2/2026 | $0 |
| | 2026 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA248018 | Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies | 002 | 5 | NIH | 4/16/2026 | $0 |
|
